Skip to main content

Johnson & Johnson Pulmonary Hypertension revenue

  • JNJ · NYSE
  • Healthcare
  • Pharmaceuticals
  • S&P 500
$285.75+0.79%Close 13 Nov 2026 · Market value $684.4B

Pulmonary Hypertension revenue at Johnson & Johnson came to $897.0M for the quarter to 27 Sep 2026, down 19.6% from a year earlier.

As Johnson & Johnson reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 21 Oct 2026.

By quarter

$1.0BMar 2025$1.1BJun 2025$1.1BSep 2025$1.2BDec 2025$1.1BMar 2026$1.1BJun 2026$897.0MSep 2026
Johnson & Johnson Pulmonary Hypertension revenue, every reported period
Period endingPulmonary Hypertension revenueChange on a yearFiled
27 Sep 2026$897.0Mdown 19.6%21 Oct 2026
28 Jun 2026$1.1Bup 2.7%23 Jul 2026
29 Mar 2026$1.1Bup 10.7%22 Apr 2026
28 Dec 2025$1.2B—11 Feb 2026
28 Sep 2025$1.1B—22 Oct 2025
29 Jun 2025$1.1B—24 Jul 2025
30 Mar 2025$1.0B—23 Apr 2025

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Johnson & Johnson: MedTech worldwide operational sales (change on a year) · Oncology revenue · Immunology revenue · Neuroscience revenue · Cardiovascular revenue · Cardiovascular/Metabolism/Other revenue · Infectious Diseases revenue · Shockwave revenue · Innovative Medicine revenue · MEDTECH revenue · United States revenue · Non-US revenue · Europe revenue · Asia-Pacific, Africa revenue · Western Hemisphere, excluding U.S. revenue · financial statements

Every KPI and segment of JNJ, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.